Jeena Sikho Lifecare Ltd Q1 FY2027 Concall Summary

Key Takeaways

• 29% YoY revenue growth, flat QoQ: The quarter's flat sequential revenue was a deliberate trade: management cut government business from ₹15 cr to ₹5 cr to avoid slow payments and bad debt, while private business kept growing.
• Ecosystem is the real story: Total connected people grew 10% QoQ to 5,34,000, which management calls the leading indicator for future IPD, product, and OPD revenue.
• Volume is running ahead of revenue: IPD volume up 33% YoY and OPD up 22%, but healthcare services revenue grew only 11%, because of the government cut, lower ticket sizes for poorer patients, and a natural lag between OPD acquisition and Panchakarma conversion.
• Advertising spend front-loaded: ₹4 cr extra ad spend hit Q1 with Colors TV and other channels; management says the patient benefit lands in Q2, and July was already the highest-ever sales and admissions month.
• What to watch next quarter: Whether the Colors TV campaign converts into admissions, whether Entero distribution actually starts within 15 days, and whether the new BPL/Ayushman discount scheme fills beds without further eroding ticket size.

The Government Business Reset

• Deliberate shutdown of credit business: Government business fell from ₹15 cr to ₹5 cr this quarter, and from ₹117 cr in FY25 to ₹35 cr last year. Management says payments take 3–6 months via NHA portal 2.0 and carry bad debt risk, so they see no benefit until timelines improve.
• The ₹10 cr decline is not operational: Management was explicit that the hospital business drop is a strategic exit from slow-paying government work, not a demand problem. Private business maintained and grew regularly.
• Mix shift follows: Services share fell to 47% from 54% a year ago because government sales, which were mostly services, disappeared.
• Reversible when payments improve: Management says government business can be scaled back up whenever NHA portal 2.0 payment timelines improve to 3–4 months.

Manish Grover: "That ₹10 crores decline in hospital business is not a drop in operational business; I deliberately shut down credit business."

Volume vs Revenue: The Conversion Lag

• The headline puzzle: IPD volume grew 33% YoY and OPD grew 22%, but healthcare services revenue grew only 11%. Management points to a 143% YoY increase in OPD, COD, and consulting patients and 65% growth in VOPD consultations.
• Three reasons for the lag: Government business in Panchakarma fell ₹10 cr; management reduced per-patient ticket size to make treatment affordable for poorer patients; and a large share of incremental OPD is first-time consultation patients still progressing through the treatment funnel.
• The funnel logic: Patients are first guided on home wellness, then convert to Panchakarma admissions later. Many skip OPD entirely and buy products directly from the website at a 5% discount.
• Discounting empty beds: Management started discounting empty beds for patients who couldn't pay, reducing ticket size. This also trains doctors ahead of the Ayushman Yojana launch.
• Repeat visits are the offset: Management reports strong second and third Panchakarma visits, which they attribute to treatment success rate.

Nanak Chand: "We are not looking for money from sick people. We are looking for money from healthy people. The money that we used to hear at home, healthy money, blessed money, good-intentioned money. We are going that way, sir."

Ecosystem & Products

• Connected people as leading indicator: Total connected people grew from 4,87,000 to 5,34,000 QoQ, a 10% jump across OPD, IPD, daycare, COD, and e-commerce. Management views this as the predictor of future IPD, product, and OPD revenue.
• Products business grew 47% YoY: Driven by a broader portfolio, expanding customer base, and increasing acceptance of quality-focused Ayurveda offerings.
• E-commerce momentum: Product sales rose ₹3 cr QoQ; e-commerce customer count rose from 2,28,000 to 2,64,000; COD orders rose 4,000–4,500; daycare volume rose from 16,700 to 19,400.
• OTC strategy is own-platform-first: Management is not launching many OTC products through medical stores because store margins are 50%. Focus is on the company's own e-commerce platform with small newspaper ads, plus Amazon and Flipkart.
• Pet Shuddhi premium justified: The ~₹800–850 premium over Pet Saffa reflects a 4x higher manufacturing cost because the product targets liver, spleen, metabolism and Agni, not just stomach cleaning.

Manish Grover: "A person who buys products later gets admitted to the hospital, and one who gets admitted later buys products. Our ecosystem develops both together."

New Initiatives: Manali, Entero, Ayushman

Ultra-luxury wellness center (Manali)

• Launching September–October: First ultra-luxury wellness model, named "Jeena Sikho Premium," located in Manali. Starting only after all NOCs are received; Himachal government laws delayed the start by a month.
• Strategic cost structure: Company bears only marketing and wage costs for doctors/healers. The owner covers front office, security, F&B, chefs, food cost, housekeeping, laundry, maintenance, and utilities.
• Deal terms: Leased property with a minimum guarantee of 35 rooms plus 80% of spa area for consultations/treatments. Three-year contract, renewable 3+3+3. Additional inventory can be added at pre-fixed rates.
• Year 1 economics: 50% occupancy, ADR ₹32,000–35,000, gross margins 50–55%, EBITDA 35–40% plus. Year 2: 60% occupancy, ~7,700 occupied room nights, ADR ₹35,000–37,000, gross operating margin 60–62%.
• Profit expectation: ₹3–5 cr net profit per center, plus brand-building that feeds customers to Meerut, Panvel/Mumbai, Lucknow, and Kurukshetra.
• FY27 impact limited: "Not much will come in 27, a lot will come in 28" because Manali has severe cold from November to February; best benefit starts from March.

Ankush Kaushal: "Such minimal operating cost is impossible in such a luxurious setup of a wellness resort, that too in the mountains. However, we have done a very strategic deal in which all we have to bear is marketing and the wage cost."

Entero distribution

• Testing complete, rollout imminent: Entero has completed testing; within 15 days, Jeena Sikho products will start appearing across all Entero distributors. Software integration and testing took the last 2 months.
• More partnerships in pipeline: Two or three more companies like Entero identified, with regular meetings ongoing.

Ayushman Yojana & BPL scheme

• Government letter on Ayurveda insurance: Four days before the call, the government issued a letter reprimanding health insurers for rejecting Ayurveda claims, directing them to reimburse properly and provide cashless, giving Ayurveda parity with Allopathy.
• Ayushman Yojana status: Government portal message indicated PMO approval; rates being set at ministry level.
• Immediate BPL scheme: Launching within 10 days a discounted admission scheme for BPL cardholders and Ayushman Yojana beneficiaries at smaller hospitals with low bed occupancy. 500 beds to start accepting poor patients at ₹4,000–6,000 ticket size.
• Preparation over waiting: Management is filling Ayushman patients on a cash/discounted basis now to build doctor practice before the scheme goes live.

Margins & Cost Structure

• EBITDA grew 17% YoY, margin at 41%: Reflecting improving operating leverage, better utilization of existing infrastructure, and increased scalability.
• Ad spend front-loaded: Advertisement expense rose ₹4 cr in Q1, a 25% increase, because 6–7 new products launched and wellness-journey content was booked on major TV channels including Saas Bhi Kabhi Bahu Thi, Anupama, Khatron Ke Khiladi, and Laughter Chef. Benefits expected in current and next quarter.
• One-time software expense: ~₹2 cr booked for a recurring/retention system where patients can schedule Panchakarma via an app every 3–6 months.
• Wage cost step-up: Government wage law changed, and its impact flowed through; management says it will now become part of routine costs.
• Other income spike: Q1 other income rose to ₹14 cr from ₹4 cr in March because of ~₹7 cr one-time items: ~₹5 cr warrant valuation and ~₹2.5 cr capital gains. Recurring other income should be ₹4–5 cr.
• Hospital PBT flat despite 11% growth: Management denied losses from new centers, attributing flat PBT to a mix shift toward day care volume, which grew 31% YoY and 16% QoQ. New centers open and pay back within 3–6 months.

Capacity, People & Systems

• Bed capacity: 100 operational beds added in Q1, taking total to 2,400; occupancy at 59%. Target is 3,000–3,500 operational beds this year, and 7,000–10,000 beds in 3–5 years with 75–80% occupancy.
• July momentum: July was the highest-ever sales month and highest-ever patient admissions, breaking June's record; August is running ahead of that.
• Panvel expansion: Currently 49 beds; OC and fire approvals in process. Once 250 beds are approved, revenue is expected to increase 4–5x.
• Doctor training: Four batches of doctors trained in the last quarter, with visible behavioral change.
• Systems overhaul: Salesforce implemented with real-time dashboards uploading data within 6 minutes; Oracle accounting software implemented; new research-based clinical protocols; increased clinical trial work; a "digital CEO" data and analytics function being built; corporate trainers hired for staff development.
• Governance upgrades: Grant Thornton is now auditor; Forvis Mazars is internal auditor, joined one year ago; new board members added for better corporate governance.
• Results timing improving: Previous quarter result came on the 30th, this quarter on the 7th–8th; management expects earlier results going forward as auditor grip increases.

Manish Grover: "We are long-term horses. We are running, right? So where we want to go, we will reach there and show. That in India, I will increase the number of people who don't fall sick more than the number of people who fall sick."

Guidance & Commitments

Key Metrics